Skip to content
ATLAS PREP HQ
Fat Loss

SLU-PP-332

Synthetic pan-estrogen-related-receptor agonist small molecule (not a peptide)

Preclinical pan-ERR agonist research examining exercise-mimetic signaling and metabolic adaptation.

Preclinical Evidence

Route

Intraperitoneal in published mouse studies. Human route has not been established.

Common format

5 mg vial

Research focus

exercise mimetics

Evidence level

Preclinical Evidence

Typical cycle

8 weeks (animal studies)

Fat Loss research motifFat Loss

SLU-PP-332 in 30 seconds

Atlas Fast Read

What it is

Synthetic pan-estrogen-related-receptor agonist small molecule (not a peptide)

Why people care

Preclinical pan-ERR agonist research examining exercise-mimetic signaling and metabolic adaptation.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Basic human safety, pharmacokinetics, oral/SC bioavailability, organ toxicity, effective human exposure, dose-response, and long-term consequences of pharmacologically activating exercise-like transcriptional pathways are all unknown.

Bottom line

SLU-PP-332 is exciting mouse biology, not a human performance drug.

Overview

What is SLU-PP-332?

SLU-PP-332 is an experimental pan-ERR agonist small molecule, not a peptide. It is included because it is commonly discussed alongside metabolic and performance peptides as a potential 'exercise-mimetic' research compound.

SLU-PP-332 was reported in the early 2020s as an experimental agonist of estrogen-related receptors that can activate an endurance-exercise transcriptional program in mice. There are no human trials.

Mechanism

How it works

Agonizes estrogen-related receptors ERRalpha/beta/gamma, activating transcriptional programs involved in mitochondrial biogenesis, oxidative metabolism, and endurance adaptation in mice.

Research areas

exercise mimeticsmitochondrial biogenesisfat oxidationendurance metabolism

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

There are no human trials. All efficacy claims are based on animal and cell research.

Preclinical evidence

Mouse studies report increased oxidative metabolism, endurance-like gene expression, energy expenditure, and reduced fat accumulation through ERR agonism. There are no human safety or efficacy data.

Knowledge gaps

Basic human safety, pharmacokinetics, oral/SC bioavailability, organ toxicity, effective human exposure, dose-response, and long-term consequences of pharmacologically activating exercise-like transcriptional pathways are all unknown.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

No human dose exists. Published mouse studies used approximately 25–50 mg/kg intraperitoneally twice daily. community sources provides mouse-equivalent microgram examples but explicitly notes that reputable sources do not support human SC dosing.

Frequency

Twice daily in the published mouse experiments.

Timing

Not applicable to humans; experimental animal protocol dependent.

Route

Intraperitoneal in published mouse studies. Human route has not been established.

Cycle length

8 weeks (animal studies)

Reconstitution

Do not treat standard peptide BAC-water instructions as established for SLU-PP-332. community sources specifically warns that bacteriostatic water can degrade this small molecule and describes sterile-water immediate preparation or laboratory solvent systems instead. Published efficacy studies are animal experiments, not a human injection protocol.

Storage

Research-chemical storage is formulation specific. community sources advises against storing SLU-PP-332 after aqueous reconstitution because of instability; supplier analytical/stability documentation should control. There is no validated human-use storage protocol.

Monitoring

No human monitoring standard because there are no human trials. Any first-in-human study would require formal toxicity, ECG, metabolic and organ-function monitoring.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human adverse effects are completely unknown. Persistent ERR activation could theoretically alter cardiac, hepatic, skeletal-muscle or metabolic physiology; animal tolerability does not establish human safety.

Contraindications

There is no human safety profile or therapeutic indication. It should not be treated as a self-experimentation compound outside formal preclinical/first-in-human research.

Interactions

No human interaction data exist. Interactions with stimulants, thyroid drugs, metabolic agents, mitochondrial compounds and exercise stress are unknown.

Stacks

Common stacks

No human stack

There are no human trials, so combining SLU-PP-332 with other metabolic/performance agents would compound unknown risk.

Preclinical only.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

SLU-PP-332 is exciting mouse biology, not a human performance drug. There is no established human dose, route, safety profile or efficacy signal, and Atlas would not convert animal mg/kg experiments into a self-use protocol.

More in Fat Loss

Fat Loss

5-Amino-1MQ

Selective NNMT-inhibitor research focused on cellular energy balance and metabolic function.

Read guide

Fat Loss

AOD-9604

Modified growth-hormone fragment studied for lipolysis and fat-metabolism effects without targeting IGF-1.

Read guide

Fat Loss

Cagrilintide

Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.

Read guide